Feb 25, 2021 / 10:00AM GMT
Layan Kalisse -
Okay. Hi, everyone. It looks like we have everyone in the room. Welcome, and thank you for joining us. Just before we start, I just want to remind everyone how this session is going to work. (Operator Instructions) And with that, I will hand it over to Siggi.
Sigurdur Oli Olafsson - Hikma Pharmaceuticals PLC - CEO & Executive Director
Thanks, Layan. Good morning, everyone. Welcome to this virtual call. This has started to be normal, which wasn't normal a year ago. So I'm not going to have a long introduction. I just want to refer you to -- that you have hopefully listened to the prerecorded presentation. So we are not going to repeat that here in the beginning of the meeting. I'm sure there's a lot of questions. I think, overall, we are very, very pleased with the result of 2020. Our core revenue up 6% to $2.3 billion, and our core operating profit up 11% to $566 million. All 3 businesses are growing organically.
Injectables business, growing 10% on top line, 12% on the bottom line. Clearly, a lot of volatility around the demand in the
Full Year 2020 Hikma Pharmaceuticals PLC Earnings Call (Q&A Session) Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers